NASDAQ$MGTX
MeiraGTx Holdings plc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
MeiraGTx's financial and operational performance for Q3 2024 was announced, featuring advancements in clinical trials and regulatory designations.
MeiraGTx reported a net loss of $39.3 million for Q3 2024, with service revenue from related parties at $10.9 million. The company highlighted clinical advancements, including positive data from the AAV-GAD bridging study for Parkinson's disease and three Rare Pediatric Disease Designations from the FDA.
- Received 3 Rare Pediatric Disease Designations (RPDD) from FDA for potential therapies.
- Agreed on pathway with MHRA for Marketing Authorization Application (MAA) for AAV-AIPL1.
- Announced positive data from randomized, sham-controlled clinical bridging study of AAV-GAD for Parkinson’s disease.
- Cash and cash equivalents totaled $122.9 million as of September 30, 2024.
Headline financials
Revenue & EPS history
MeiraGTx · Revenue · Quarterly
$10.9M
Forward guidance
MeiraGTx anticipates several milestones, including data from the Phase 3 LUMEOS trial of botaretigene sparoparvovec and initiation of first in human studies using the riboswitch platform for an undisclosed metabolic disease indication in 2025.
Tailwinds
- Data from the Phase 3 LUMEOS trial of botaretigene sparoparvovec is expected towards the end of this year.
- Eligible to receive up to $285 million upon the first commercial sales of bota-vec in the U.S. and EU and manufacturing tech transfer.
- Entered into a commercial supply agreement with Johnson & Johnson Innovative Medicine for bota-vec manufacturing.
- Continue to progress its riboswitch technology platform in multiple potential indications.
- Intends to initiate first in human studies using the riboswitch platform for an undisclosed metabolic disease indication in 2025.
Headwinds
- Incurrence of significant losses.
- Inability to achieve or maintain profitability.
- Failure to raise additional capital.
- Failure to repay our debt obligations.
- Failure to identify additional and develop existing product candidates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
+0.1%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-0.0%
Avg return
30 days after
31%
10 / 32 earnings
Positive
+25.0%
Q1 2019
Best reaction
-20.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.0% | -6.1% | — | |
| Q1 2026 | -0.2% | -8.4% | -3.7% | |
| Q3 2025 | -4.5% | -10.5% | +3.0% | |
| Q2 2025 | -0.1% | -9.1% | -8.8% | |
| Q1 2025 | -0.4% | +5.2% | +31.5% | |
| Q4 2024 | +1.3% | +17.0% | -18.9% | |
| Q3 2024 | -0.3% | -8.6% | -8.1% | |
| Q2 2024 | -3.4% | -3.2% | -4.8% | |
| Q1 2024 | -1.4% | +1.8% | -7.2% | |
| Q4 2023 | +0.0% | -1.1% | -12.4% | |
| Q3 2023 | +4.7% | +19.2% | -1.3% | |
| Q2 2023 | +5.6% | +1.6% | -3.8% | |
| Q1 2023 | -6.9% | +12.9% | +30.2% | |
| Q4 2022 | -3.4% | -11.9% | -8.3% | |
| Q3 2022 | -7.3% | -6.3% | -13.2% | |
| Q2 2022 | +14.4% | +7.0% | -5.9% | |
| Q1 2022 | -3.1% | -5.9% | -15.0% | |
| Q4 2021 | -2.4% | -5.0% | -7.1% | |
| Q3 2021 | -1.7% | -1.7% | +1.8% | |
| Q2 2021 | -0.9% | -8.3% | -16.2% | |
| Q1 2021 | -2.4% | -3.7% | +10.2% | |
| Q4 2020 | +8.0% | +9.1% | -17.3% | |
| Q3 2020 | -1.7% | +4.1% | -6.9% | |
| Q2 2020 | +5.1% | +5.6% | -3.7% | |
| Q1 2020 | +7.8% | +16.1% | +8.0% | |
| Q4 2019 | -20.4% | -38.8% | -11.1% | |
| Q3 2019 | +1.7% | +6.7% | +49.4% | |
| Q2 2019 | -10.6% | -15.2% | -22.9% | |
| Q1 2019 | +25.0% | +32.1% | +23.5% | |
| Q4 2018 | -3.0% | -3.7% | +3.4% | |
| Q3 2018 | -2.6% | -5.3% | -5.5% | |
| Q2 2018 | +7.9% | +6.2% | +40.7% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro